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Abstract 
Background: Tumour resistance to a wide range of drugs (multiple drug resistant, MDR) acquired after intensive 
chemotherapy is considered to be the main obstacle of the curative treatment of cancer patients. Recent work has 
shown that oncolytic viruses demonstrated prominent potential for effective treatment of diverse cancers. Here, we 
evaluated whether genetically modified vaccinia virus (LIVP-GFP) may be effective in treatment of cancers displaying 
MDR phenotype.
Methods: LIVP-GFP replication, transgene expression and cytopathic effects were analysed in human cervical carci-
nomas KB-3-1 (MDR−), KB-8-5 (MDR+) and in murine melanoma B-16 (MDR−), murine lymphosarcomas RLS and RLS-
40 (MDR+). To investigate the efficacy of this therapy in vivo, we treated immunocompetent mice bearing murine 
lymphosarcoma RLS-40 (MDR+) (6- to 8-week-old female CBA mice; n = 10/group) or melanoma B-16 (MDR−) (6- to 
8-week-old female C57Bl mice; n = 6/group) with LIVP-GFP (5 × 107 PFU of virus in 0.1 mL of IMDM immediately and 
4 days after tumour implantation).
Results: We demonstrated that LIVP-GFP replication was effective in human cervical carcinomas KB-3-1 (MDR−) and 
KB-8-5 (MDR+) and in murine melanoma B-16 (MDR−), whereas active viral production was not detected in murine 
lymphosarcomas RLS and RLS-40 (MDR+). Additionally, it was found that in tumour models in immunocompetent 
mice under the optimized regimen intratumoural injections of LIVP-GFP significantly inhibited melanoma B16 (33 % 
of mice were with complete response after 90 days) and RLS-40 tumour growth (fourfold increase in tumour doubling 
time) as well as metastasis.
Conclusion: The anti-tumour activity of LIVP-GFP is a result of direct oncolysis of tumour cells in case of melanoma 
B-16 because the virus effectively replicates and destroys these cells, and virus-mediated activation of the host 
immune system followed by immunologically mediated destruction of of tumour cells in case of lymphosarcoma 
RLS-40. Thus, the recombinant vaccinia virus LIVP-GFP is able to inhibit the growth of malignant cells with the MDR 
phenotype and tumour metastasis when administered in the early stages of tumour development.
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Background
The armamentarium to treat cancer today includes a 
variety of methods such as surgery, radio- and chemo- 
and targeted therapy. One of the important problems 
associated with anticancer therapy is the emergence 
of tumour cell populations that are heterogeneous and 
resistant to a broad spectrum of chemotherapeutics, 
which leads to cancer recurrence. In addition, the resist-
ance of cancer cells to targeted therapeutics has recently 
been demonstrated. Several mechanisms are known to 
mediate tumour resistance to anticancer drugs, includ-
ing increased DNA damage repair [1], reduced apoptosis 
Open Access
Journal of 
Translational Medicine
*Correspondence:  marzen@niboch.nsc.ru 
1 Institute of Chemical Biology and Fundamental Medicine SB RAS, 8, 
Lavrentiev ave., Novosibirsk 630090, Russian Federation
Full list of author information is available at the end of the article
Page 2 of 14Goncharova et al. J Transl Med  (2016) 14:241 
[2], altered drug metabolism [3], and increased efflux of 
anticancer agents that enter the cells by diffusion to the 
plasma membrane [4]. Efflux of anticancer agents refers to 
multidrug resistance (MDR) that is acquired after inten-
sive chemotherapy. One of the mechanisms of MDR is the 
overproduction of P-glycoprotein (P-gp), which acts as an 
efflux pump for various anticancer drugs [1, 5, 6]. MDR 
severely limits the effectiveness of chemotherapy and is 
responsible for the overall poor efficacy of cancer treat-
ment [7–9]. Faced with these challenges, the development 
of more effective anti-cancer drugs capable of coping with 
MDR is an urgent task for the scientific community.
The genetic modification of oncolytic viruses (OVs) is 
considered to be one of the most exciting new areas of 
cancer therapy [10–12]. Currently, viruses from nine dif-
ferent families are being used for anti-cancer therapeu-
tic development including Adenoviridae, Picornaviridae, 
Herpesviridae, Paramyxoviridae, Parvoviridae, Reoviri-
dae, Poxviridae, Retroviridae and Rhabdoviridae [13–16]. 
The OVs have specific tissue tropisms enabling them 
to selectively infect and kill tumour cells with minimal 
impact on normal tissue [17]. Given that the mechanism 
of OVs not only involves direct tumour cell destruction, 
but also the indirect eradication of target cells express-
ing viral antigens as a result of immune recognition of 
these cells, one could assume that the utilization of OVs 
in MDR tumour therapy is likely to succeed.
Vaccinia virus has some very attractive advantages 
among other oncolytic virus candidates [18]. Above all, it 
should be noted that the virus has a widespread historical 
use due to the Smallpox Eradication Program [19, 20]. At 
the same time, such peculiarities of the vaccinia virus life 
cycle such as rapid replication cycle taking place in the cell 
cytoplasm, extracellular enveloped viral particles having 
the extra envelope formed with host complement control 
proteins, and large capacity of the viral DNA to tolerate 
the insertion or/and deletion of large genes make the virus 
an appealing oncolytic agent [18, 21, 22]. The efficacy of 
using oncolytic viruses in therapy of several cancer types 
has been established [23–25]. Antitumour drugs based on 
oncolytic viruses are currently undergoing various phases 
of clinical trials [26, 27]. Nevertheless, there is relatively 
poor information about utilizing oncolytic viruses to treat 
cancers displaying the MDR phenotype.
In this study, we examined the efficacy of genetically 
modified vaccinia virus (VACV) with disruption of the 
viral thymidine kinase gene (TK) with respect to cancer 
cells with the MDR phenotype in  vitro and in  vivo. We 
demonstrated that vaccinia virus administered in the 
early phase of tumour development is able to quite suc-
cessfully suppress the growth of MDR malignant cells, as 
well as prevent metastasis and activate the host immune 
system.
Methods
Cell lines and virus
Mouse melanoma B-16-F10 (here and after B-16), mouse 
lymphosarcoma RLS, drug resistant mouse lymphosar-
coma RLS-40, human cervical carcinoma KB-3-1, drug 
resistant human cervical carcinoma KB-8-5, African 
green monkey kidney fibroblast CV-1 cells were obtained 
from the Culture Collection of the Institute of Chemical 
Biology and Fundamental Medicine, Siberian Branch of 
the Russian Academy of Sciences. B-16, RLS and KB-3-1 
cells were cultured in IMDM containing 10  % foetal 
calf serum (FCS) and with antibiotic–antimycotic solu-
tion (100  U/mL penicillin G, 100  U/mL streptomycin, 
250 ng/mL amphotericin B) at 5 % CO2 and 37 °C (stand-
ard conditions). RLS-40 and KB-8-5 cells were cultured 
in IMDM with 40  nM Vincaleukoblastine sulfate salt 
(Sigma) under standard conditions.
Vaccinia virus LIVP-GFP was modified by deletion of 
the thymidine kinase gene and by insertion of the DNA 
sequence encoding the green fluorescent protein (GFP) 
protein. The construction of mutant vaccinia virus LIVP-
GFP was described recently [28].
Cytotoxicity assay
The viability of cells after infection with virus was meas-
ured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) (Sigma) based assay 
[29]. Cells were plated in 96-well plates at the following 
concentrations for adherent cell cultures: 9  ×  103 cells 
per well for KB-3-1 and KB-8-5, 3  ×  103 for B-16 and 
incubated under standard conditions. When cell densi-
ties reached 80  % confluence for adherent cells and for 
suspension cell cultures of RLS and RLS-40 at a concen-
tration of 1 × 105 cells per well, cells were washed with 
PBS and incubated with the virus at 1 or 10 PFU/cell in 
serum-free media for 1 h. Then, the medium containing 
the virus was removed, and the cells were incubated in 
the same medium containing 2 % FCS at 37 °C for 72 h. 
A 5  mg/mL MTT solution was added to the cells to a 
concentration of 0.5  mg/mL, and the cells were incu-
bated for 3 h under standard conditions. After removal of 
MTT-containing medium, the crystals of formazan were 
dissolved in 200  μL of DMSO, and the optical density 
was measured using a Multiscan RC multichannel pho-
tometer (Labsystems, Finland) at wavelengths of 570 and 
620  nm. The data were presented as the percentage of 
viable cells, with the number of cells in the control wells 
incubated in the absence of the virus set at 100 %.
Microscopic studies
Confocal fluorescence 2D imaging was performed on 
LSM 710 confocal laser scanning microscope (Carl Zeiss, 
Germany) with an objective lens (×10). The argon gas 
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laser line of 488 nm was used to excite GFP. To acquire 
non-confocal transmitted light images in bright field 
transmitted light detector (T-PMT) was used. For illus-
tration purposes green channel was extracted from the 
merged pictures with the ZEN 2011 Black edition soft-
ware (Zeiss).
Flow cytometry analysis of GFP protein expression
At 24, 48 and 72 h following viral infection, cancer cells 
were detached by trypsin (when applicable), fixed in a 
2 % solution of formaldehyde in PBS, and GFP expression 
was analysed with a Cytomics FC 500 CXP flow cytome-
ter (Beckman Coulter, United States), no less than 15,000 
events/sample. The cells were considered GFP-positive if 
the level of their fluorescence exceeded the autofluores-
cence of cells in the control group by at least a factor of 
five. The intensity of fluorescence of individual cells was 
measured in relative fluorescence units (RFU) at a laser 
excitation wavelength of 488 nm.
Viral proliferation assay
Standard plaque forming assay was performed to quan-
tify viral replication following infection of different can-
cer lines with LIVP–GFP. The cells were infected with 
LIVP–GFP virus at a multiplicity of infection (MOI) of 
1 or 10 PFU/cells for 1  h at 37  °C and 5  % CO2. At 24, 
48 and 72 h after infection, tumour cells were harvested 
and lysates were prepared by freeze-thawing and sonica-
tion in IMDM media with 2 % FBS. The viral titres were 
determined by plaque forming assay using CV-1 cells as 
described in [30].
Tumour development
6- to 8-week-old immunocompetent female C57Bl/6 and 
CBA/LacSto mice (here and after C57Bl and CBA mice, 
respectively) were purchased from vivarium of the State 
Research Center of Virology and Biotechnology “VEC-
TOR”. Animals were kept in the vivarium of the Insti-
tute of Chemical Biology and Fundamental Medicine, SB 
RAS, with a natural light regimen on a standard diet for 
laboratory animals [GOST (State Standard) R 5025892] 
in compliance with the international recommendations 
of the European Convention for the Protection of ver-
tebrate animals used for experimental studies (1997), 
as well as the rules of laboratory practice in the perfor-
mance of pre-clinical studies in the Russian State Stand-
ards (R 51000.3-96 and 51000.4-96). The experimental 
protocols were approved by the Committee on the Ethics 
of Animal Experiments with the Institute of Cytology and 
Genetics of the Siberian Branch of the Russian Academy 
of Sciences.
B-16 tumour cells (1.5 ×  105/100 μL in IMDM) were 
subcutaneously (sc) injected into the right flank of 
6- to 8-week-old female C57Bl mice. RLS-40 tumour 
cells were intramuscularly injected into the right thighs 
of CBA mice. The mice then received 5  ×  107 PFU of 
LIVP-GFP virus in 0.1  mL of IMDM into the site of 
tumour implantation immediately and 4  days after 
implantation. The control animals received 0.1  mL of 
IMDM only. Animals were observed daily for any sign 
of toxicity, and body weight was checked twice a week. 
Tumour growth was recorded in three dimensions using 
a digital calliper. Tumour volume was calculated as 
[(length × width2)/2] and reported in mm3. The median 
survival time is defined as the animal’s life span from the 
inoculation of tumour cells until death. The tumour vol-
ume doubling time (TDT) calculated using the equation 
TDT =  (tmax−t0) ×  ln2/(lnVmax−lnV0), where tmax−t0 is 
the time between measurements; V0 is the volume of the 
tumour at the time t0; Vmax is the tumour volume at the 
time tmax.
Vaccinia viral titres in RLS‑40 tumour
CBA mice received 5 × 107 PFU of LIVP-GFP virus into 
tumours on day 12 after tumour implantation in the 
right thigh. To determine the level of viral reproduction 
in mice without tumour implantation the control ani-
mals received the same dose of virus in the right thigh. 
Then the right thigh of three virus-treated animals were 
excised at 1, 2, 3, 4 days post injection and frozen. Sam-
ples were then homogenized in IMDM supplemented 
with 2  % FBS using an ULTRA-TURRAX (IKA), and 
supernatants were collected by centrifugation (3500g, 
5  min, 4  °C). Viral titres were measured by standard 
plaque assays on CV-1 cells.
Expression of the virus‑encoded marker gene GFP in vivo
C57Bl mice were implanted with B-16 tumour cells 
(1.5 × 105 cells in 100 μL IMDM) into the foot pad. On 
day 18 after cell implantation, when the median tumour 
volume reached approximately 100 mm3, a single dose of 
virus (1 × 108 PFU in 100 IMDM) was injected intratu-
mourally. GFP expression within tumours was monitored 
each 24 h post infection using a stereo fluorescence mac-
roimaging system (Lightools Research).
IFN‑γ ELISPOT assay
The number of LIVP-GFP-specific IFN-γ-secreting cells 
in mice was counted using commercial ELISPOT assay 
kits (BD Biosciences, USA) according to the manufactur-
er’s instructions. Briefly, antimouse IFN-γ monoclonal 
antibodies were coated on multiscreen 96-well plates at 
4 °C overnight. Next, the plates were washed three times 
and blocked for 2  h with RPMI 1640 containing 10  % 
FCS at room temperature. Spleen cells were obtained 
after the red cells in the spleen cell suspension were 
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lysed. Then the freshly isolated splenocytes (5  ×  105) 
were transferred to each well and LIVP-GPF was added 
at MOI of 0.1. Cells incubated in the absence of virus 
were used as a negative control and cells incubated with 
concanavalin A (10  µg/mL) were used as positive con-
trols. Following incubation at 37  °C for 24  h and 5  % 
CO2, the cell suspensions were aspirated, washed four 
times with PBST, biotinylated detection antibody was 
added, and the plates were incubated for 2  h at room 
temperature. After four washes, streptavidin horserad-
ish peroxidase antibody was added. Following four more 
washes, freshly prepared 3-amino-9-ethylcarbazole sub-
strate solution was added for 15–30  min at room tem-
perature in the dark to yield colored spots. Finally, the 
reaction was stopped by thoroughly rinsing with tap 
water. The plates were air-dried and the number of the 
spots was calculated.
Evaluation of the pathogenic and toxic effects of LIVP–GFP 
virus
Each of the experimental groups contained four 7-week-
old female C57Bl mice. The animals were infected intra-
peritoneally with the virus at doses of 104, 106, and 108 
PFU/mouse in 0.2  mL of IMDM. The mice from the 
control group were administered with the same volume 
of IMDM only. After the injection, the signs of intoxica-
tion (including general condition, weight, and depression 
of the central nervous system) were assessed daily for 
21 days.
Histological studies
For morphometric analysis, the livers were fixed in 
10 % neutral-buffered formalin, routinely processed and 
embedded in paraffin. Paraffin sections (5  μm) were 
stained with haematoxylin and eosin, microscopically 
examined and scanned. Images were obtained using a 
microscope Axiostar plus equipped with an Axiocam 
MRc5 digital camera (Zeiss, Germany).
The number and area of internal metastases and 
destructive changes in the liver were quantified in 10–15 
randomly selected microscopic fields in each specimen.
The percentages of the internal metastatic areas were 
determined relative to the total area of each liver section 
(magnification 100×) using Adobe Photoshop software. 
Stereological quantification of the liver samples was per-
formed by point counting, using a closed test-system at 
a 400× magnification. The test-system used had 100 
testing points in a testing area equal to 3.2 ×  106  μm2. 
The volume densities (Vv) of normal liver parenchyma, 
hepatocytes with degenerate and necrotic changes and 
numerical density (Nv) of binuclear hepatocytes reflect-
ing the regeneration capacity of the liver were evaluated 
as described in [31].
Evaluation of cytokine levels in the blood serum of mice
Blood collection of mice was carried out under anaesthe-
sia by a heparinised capillary pipet (No. 554/20, Assist-
ent, Sondheim, Germany) via the retroorbital sinus vein. 
Blood serum was prepared by clot formation at 37 °C for 
30 min and at 4 °C overnight followed by clot discard and 
serum centrifugation (2000g, 4 °C). Serum samples were 
stored at −20 °C until analysis. The levels of TNF-α, IL-6, 
GM-CSF and IFN-γ in the blood serum of mice were 
measured using Colorimetric ELISA Kits (ThermoSci-
entific, USA) according to the manufacturer’s protocols. 
Absorbance was measured at 450 nm using a plate-read-
ing spectrophotometer Multiscan RC multichannel pho-
tometer (Labsystems, Finland).
Statistical analyses
A two-tailed Student’s t test was used for statistical 
analysis except for comparison of survival curves, where 
a Wilcoxon-Rank test was used. P values of ≤0.05 were 
considered statistically significant.
Results
The recombinant VACV strain LIVP-GFP containing the 
gfp gene inserted in the thymidine kinase locus of the 
virus was constructed at the State Research Center of 
Virology and Biotechnology “VECTOR” [28]. The inser-
tion of gfp was verified by sequence analysis as well as 
GFP production in the CV-1 African green monkey cell 
line infected with the virus. The strain was deposited in 
the Vector’ Collection of Cultures of Microorganisms 
and called LIVP–GFP. Insertion of the DNA sequence 
encoding GFP into the thymidine kinase (TK) gene sig-
nificantly improves tracking of the virus without interfer-
ing with its ability to replicate. Moreover, insertion of the 
GFP gene into the TK gene of VACV significantly reduces 
its ability to reproduce in the majority of normal cells, 
because viral replication is dependent on cellular thymi-
dine kinase, which is transiently expressed in normal cells 
during S phase of the cell cycle [32]. Most of the tumour 
cells constitutively express thymidine kinase, allowing the 
recombinant virus with defective thymidine kinase gene 
to replicate selectively in these cells [33].
Cytotoxicity of LIVP‑GFP with respect to human and mouse 
cancer cell lines
To determine the antitumour potential of vaccinia virus 
strain LIVP–GFP, we examined its cytotoxic behaviour 
(oncolytic activity) with respect to tumour cells of differ-
ent origin: B-16 (murine melanoma), KB-3-1 (human cer-
vical carcinoma), RLS (murine lymphosarcoma), as well 
as tumour cell lines with the multidrug resistance phe-
notype (MDR): КB-8-5 (human cervical carcinoma) [34] 
and RLS-40 (murine lymphosarcoma) [35]. KB-8-5 is cell 
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line generated from the KB-3-1 cell line in the presence 
of 10  ng/ml colchicine and more resistant to colchicine 
than its parental cell line and cross-resistant to adriamy-
cin, vincristine, vinblastine, actinomycin D, and puromy-
cin [34]. The MDR phenotype of KB-8-5 cells is associated 
with overexpression of the mdr1 gene followed by over-
expression of the ATP-binding cassette (ABC) transporter 
P-glycoprotein (ABCB1) [36]. The MDR of the RLS-40 
murine lymphosarcoma cells (RLS parental line) is also 
associated with overexpression of ABC-transporter genes 
mdr1a/mdr1b [37]. It should be noted that RLS cells 
are also drug resistant, but mainly due to the increased 
expression of Bcl-2 protein, which is a member of the 
anti-apoptotic BCL-2 family of proteins [37]. Obtained 
vinblastine, doxorubicin and cytarabine IC50 values were 
50, 46 and 3 times higher for the RLS-40 cell line than the 
values in the parental line, respectively [37].
The degree of tumour cell killing during the develop-
ment of infection was determined 24, 48 and 72 h after 
the infection with the virus LIVP–GFP (MOI 1) using 
the MTT assay (Fig. 1). B-16 and KB-3-1 cells were the 
most susceptible to the virus, having only 57 and 64  % 
of surviving cells at 24  hpi, and 22 and 17  % at 72  hpi, 
respectively. The susceptibility of the MDR + KB-8-5 and 
RLS-40 cells was lower in comparison with the paren-
tal lines. The virus destroyed 65  % of the KB-8-5 cells 
by 72 hpi, whereas 83 % of the parental KB-3-1 cell died 
under these conditions. Both RLS (increased expression 
of bcl-2) and RLS-40 (overexpression of mdr1a/mdr1b 
genes) lymphosarcoma cells showing different types of 
drug resistance were less susceptible to the virus than 
KB-3-1 and B-16 cells. Moreover, approximately 50 % of 
RLS cells died by 72 hpi, whereas the RLS-40 cell popula-
tion was reduced by 20  % at this time point. Thus, one 
can conclude that the cells with the MDR phenotype are 
less susceptible to the virus.
Confocal microscopy was used to follow the develop-
ment of infection in the cells. Figure  1b displays repre-
sentative images of the cells 24 hpi obtained in fluorescent 
and bright field modes. It can be seen that in populations 
of B-16, KB-3-1 and KB-8-5 but not RLS cells efficient 
expression of viral proteins (based on the appearance of 
GFP-positive cells) takes place. At this time point (24 hpi) 
a number of cells already changed their shape (cell bleb-
bing) thus indicating that the cells are close to collapse. 
It is worth mentioning that cell blebbing is observed for 
cells with the brightest green fluorescence corresponding 
to the development of infection. The data of MTT assay 
coincide well with confocal microscopy data.
Viral replication
The cytopathic effect of the virus depends on the effi-
ciency of the development of productive viral infection, 
which can be estimated by the accumulation of viral 
particles in the infected cells. We compared LIVP-GFP 
reproduction in MDR-positive KB-8-5 and RLS-40 cells 
with matched parental KB-3-1 and RLS cells, as well as 
with B-16 murine melanoma cells. A maximum repro-
duction of the virus at MOI 1 was observed in KB-8-5 
and KB-3-1 cells, indicating an efficient development 
of viral infection in these cells. The viral titre in KB-3-1 
and KB-8-5 cells reached 6.1 and 6.9 lg PFU/mL, respec-
tively (Fig. 2a). A tenfold MOI increase did not result in 
a concomitant increase in viral titre (Fig.  2b). The viral 
Fig. 1 Cytopathic effect of LIVP–GFP on different tumour cells.  
a MTT assay data. The cells were infected with LIVP–GFP virus at MOI 
of 1. The mock-infected cells were used as a control, and the number 
of viable cells in the control was set at 100 %. The values are the 
mean ± SEM of triplicate samples. b Confocal fluorescent (Left) and 
non-confocal transmitted light images in bright field (Right) (merge 
is shown in the middle) of tumour cells 24 h post infection with LIVP-
GFP at MOI of 1
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titre increased in B-16 cells in a similar way where val-
ues reached 5.8  lg  PFU/ml during the first 24  h after 
infection and remained the same at 48  hpi. In turn, 
viral reproduction in lymphosarcomas RLS and bRLS-
40 was much less effective: no effective viral produc-
tion was detected in RLS-40 cells at any MOI and only 
an increase by an order of magnitude in viral titre was 
observed in infected RLS cell populations at 48 hpi and 
at MOI 1 (Fig. 2a).
Analysis of expression of viral protein in infected cells
The level of susceptibility of tumour cells to infection 
induced by LIVP–GFP in vitro was evaluated using flow 
cytometry based on the appearance of GFP-positive cells 
(i.e., cells in which the viral proteins are expressed).
A progressive increase in the number of cells express-
ing GFP was detected for B-16, KB-3-1 and KB-8-5 
cell lines and 86 % of KB-3-1, 67 % of KB-8-5 and 89 % 
of B-16 cells produced GFP within 24  hpi (cells were 
infected at MOI 1) (Fig.  3a, c). GFP production rates 
were significantly less for RLS and RLS-40 cells: 7–9 % 
of RLS cells and 6–8  % of RLS-40 cells expressed GFP 
by 24 and 48 hpi. The mean fluorescence intensity (MFI) 
in B-16, KB-3-1 and KB-8-5 cells was much higher than 
the intensity in RLS/RLS-40 cells at MOI 1 (Fig. 3b, c). 
A tenfold MOI increase resulted in a significant increase 
of GFP-positive RLS and RLS-40 cells, (37 and 60  %, 
respectively; primary data shown in Additional file  1: 
Figure S1) and significantly altered the MFI for these cell 
lines (Fig. 3b).
Analysis of GFP expression in vivo
Analysis of virus replication in an immunocompetent 
in  vivo model is an important step in the estimation 
of antitumour efficacy of LIVP-GFP virus. A total of 
1.5 × 105 of melanoma B-16 cells was implanted subcuta-
neously into the footpad of C57BL/6 mice. After 18 days, 
LIVP-GFP was injected into formed tumours. In  vivo 
imaging was performed on days 1, 2, 3, 5 and 8 after virus 
injection. Expression of viral proteins monitored by GFP 
expression levels was observed on day 3 after intratu-
moural virus injection and continued well-marked up to 
day 5 (Fig. 4a, b). In other organs and tissues fluorescence 
was not detected.
Due to the relatively low sensitivity of the in  vivo 
imaging, the dynamics of virus replication in RLS-40 
tumours was analysed by determination of the virus titre 
in tumour tissue homogenates for 5  days after intratu-
moural injection of the virus (Fig. 4b). Virus injection was 
performed on day 12 after tumour implantation when 
the tumour became palpable. The data on the reproduc-
tion of the virus in  vivo confirmed the results obtained 
in  vitro. The amount of infectious virus in the samples 
collected at 24 and 48  hpi was continuously decreased 
and no virus was detected in the tumour at 72 hpi.
LIVP‑GFP therapeutic efficacy analysis
Pathogenic and toxic properties of the virus were evalu-
ated prior to the study on its antitumour effect. Tumour-
free C57Bl/6 and CBA mice were intraperitoneally 
injected with different doses of the virus. A single injec-
tion of the virus in a maximum dose of 108 PFU/mouse 
did not cause significant weight loss, changes in general 
condition or death of the mice, indicating low toxicity of 
the virus.
The antitumour effect of LIVP-GFP at 5  ×  107 PFU 
dose was evaluated in immunocompetent mice using two 
generated tumour models of B16 melanoma/C57Bl and 
Fig. 2 Development of LIVP-GFP infection in various tumour cells. 
Development of LIVP-GFP infection in RLS (green circles), RLS-40 (red 
circles), KB-3-1 (violet squares), KB-8-5 (black line with open squares) and 
melanoma B-16 (blue triangles) tumour cells at MOI of 1 (a) and MOI 
of 10 (b). Cells were incubated with virus for 1 h, washed with PBS 
and incubated up to the analysis in IMDM supplemented with 2 % 
FBS. Viral titre was measured by PFU assay. Data of three independent 
experiments are presented
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lymphosarcoma RLS-40/CBA without and with the MDR 
phenotype, respectively. Melanoma B-16 tumour cells 
were implanted intradermally in a dose of 2 × 105 cells/
mouse. The virus (n  =  6/group) or PBS (n  =  7/group) 
was injected intradermally immediately after implanta-
tion and intratumourally 4  days after cell implantation 
(Fig.  5a). Tumour growth was quantitated by measur-
ing tumour volume every 2–3 days. Figure 5b shows the 
dynamics of primary tumour growth in mice receiving 
LIVP-GFP or PBS. The results show that despite the obvi-
ous scatter in the data obtained by measuring tumour 
size, the average tumour volume was significantly smaller 
in the virus-treated group than in the control group 
(Fig. 5b). It should be noted that about half of the mice 
in virus-treated groups responded to the treatment, and 
virus therapy resulted in complete inhibition of tumour 
development in 33 % of the animals (Fig. 5c). Mice with 
complete responses were followed for up to 90 days with 
no evidence of tumour relapse or any toxicity attributable 
to the therapy.
To elucidate the antitumour activity induced by LIVP-
GFP in replication-resistant lymphosarcoma RLS-40, 
the mice were intramuscularly implanted with RLS-40 
cells and injected with the virus (n =  10/group) or PBS 
(n  =  10/group) in the same location immediately after 
and 4 days after the implantation (Fig. 5a). Several mice 
(n = 3) were taken for histological examination on day 15 
after the implantation. The data show a significant delay 
in tumour growth in the virus-treated animals (Fig. 5d). 
Analysis of tumour growth dynamics showed a 77  % 
reduction in tumour growth on day 13 after tumour ini-
tiation in the groups of mice treated twice with virus. At 
the end of the experiment, inhibition of tumour growth 
in this group was almost 85 %. The parameter that char-
acterizes the intensity of tumour growth is the tumour 
doubling time (TDT). In the animals of the control group 
TDT was 1.7 ± 1.6 days, whereas in the animals from the 
experimental group TDT was 7.8 ± 3.9 days, indicating 
that antitumour therapy is efficient using LIVP-GFP in 
RLS-40 tumours.
Morphometric analysis of histological sections of the 
livers of experimental animals revealed that the number 
of metastases in the group of mice treated with LIVP-
GFP fluctuated significantly from 3 to 24, however the 
relative area occupied by metastases was almost tenfold 
less in this group in comparison to the PBS-treated group 
(Fig. 5e). Histopathological analysis of the liver tissue of 
RLS-40-bearing mice treated with PBS revealed diffuse 
and focal metastatic infiltration of the liver by tumour 
cells located predominantly surrounding the blood ves-
sels (Fig. 6). Development of RLS-40 metastatic infiltra-
tion of the liver by tumour cells treated with PBS was 
Fig. 3 Expression of LIVP-GFP viral protein in various cell lines. The flow cytometry data. a Cells were infected with LIVP-GFP (MOI 1), and the per-
centage of GFP-positive cells was evaluated 24 h (grey bars) and 48 h (dark grey bars) post infection (hpi). GFP-positive cells were those with fluores-
cence intensities at least twice that of the autofluorescence intensities of non-infected cells. b Mean fluorescence intensities of the cell population 
infected with LIVP-GFP at MOI of 1 (grey bars) and MOI of 10 (dark grey bars) in comparison with the control cells at 24 hpi. c The original images of 
flow cytometry showing development of LIVP-GRF infection in tumour cells 2 and 24 hpi
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accompanied with severe destructive changes and dis-
turbed circulation in the adjacent liver tissue (dilatation 
and congestion in central vein, destruction of hepatic 
lobule structure, protein degeneration of hepatocytes, 
frequent monocellular and focal necrosis). The treat-
ment of RLS-40-bearing animals with LIVP-GFP was 
accompanied by a less pronounced infiltration of the 
liver parenchyma by tumour cells compared to that of the 
control animals. Moreover, intratumoural injections of 
virus were associated with a decrease in the percentage 
and depth of dyscirculatory and destructive changes 
in the liver parenchyma. The portion of hepatocytes 
with dystrophic changes (moderate protein dystrophy) 
and necrosis of the liver parenchyma (rare monocellu-
lar necrosis) was reduced. The volume density of total 
destructive changes in the liver of the RLS-40-bearing 
animals treated with LIVP-GFP decreased 2.1-fold in 
comparison with the RLS-40-bearing mice without treat-
ment (see Additional file 1: Table S1).
Evaluation of LIVP‑GFP‑associated immune response 
activation
Taking into account the fact that the virus effectively 
inhibits the development of tumours in mice implanted 
with lymphosarcoma RLS-40 cells, but does not effec-
tively replicate in these cells (Figs.  3, 4b), in contrast to 
the productive viral replication that occurs in melanoma 
B-16 cells, one could assume that the host immune sys-
tem might be a factor determining the efficacy of the 
virotherapy. To test this hypothesis, mice were implanted 
with lymphosarcoma RLS-40 cells into the right femoral 
muscle or subcutaneously with melanoma B-16 cells. The 
virus was injected in a dose of 5 × 107 PFU/mouse in the 
tumour site immediately after and 4  days following the 
implantation. The control group was injected with PBS. 
Splenocytes were obtained from all groups 3  days after 
the second virus injection, and the activation of the T-cell 
host immune system was evaluated by quantifying the 
number of virus-specific IFN-γ-secreting cells (Fig.  7a). 
LIVP-GFP injection resulted in a ten-fold increase of 
virus-specific IFN-γ-secreting cells in both B-16 and 
RLS-40 tumour-bearing mice, thus, indicating the stimu-
lation of a T-cell immune response (Fig. 7a).
For further analysis of the immunological mechanisms 
involved in the growth inhibition of lymphosarcoma 
RLS-40 after virus injection, and given the evidence of 
the virus-mediated induction of various pro-inflamma-
tory mediators and cytokines, we assessed the kinetics of 
GM-CSF, IFN-γ, TNF-α and IL-6 in the serum of RLS-
40-bearing mice treated with the virus or PBS. The levels 
of GM-CSF, IFN-γ and TNF-α in both experimental and 
control groups showed no significant change during the 
monitoring period (Fig.  7b, data referred to GM-CSF). 
A significant increase in the IL-6 concentration in mice 
treated with PBS (but not with the virus) was observed. 
The elevated IL-6 levels correlated with intensive tumour 
growth in this group (Figs. 5d, 7c).
Discussion
The aim of the study was to investigate LIVP-GFP repli-
cation efficacy in MDR cancer cells, its ability to destroy 
these cells in  vitro and determine whether such viro-
therapy can be used to treat MDR tumours in vivo. The 
Fig. 4 Development of LIVP-GFP virus in mice in the place of injec-
tion. a, b Imaging of animals with melanoma B-16 cells implanted in 
the mouse footpads followed by LIVP-GFP virus administration. Mice 
were imaged at 1 (a) and 5 (b) days post infection. The arrow shows 
the fluorescence of the tumour area infected with LIVP-GFP. c The 
titre of LIVP-GFP virus in the place of injection of mice with intramus-
cularly implanted RLS-40 cells (dark grey) and in healthy animals (grey) 
receiving the same dose of virus intramuscularly. The data of two 
independent experiments are presented
Page 9 of 14Goncharova et al. J Transl Med  (2016) 14:241 
human carcinoma KB-8-5 cell line with mdr1 overex-
pression (parental cell line KB-3-1) [34] and murine 
lymphosarcoma RLS-40 cell line with mdr1a/mdr1b 
overexpression [37] were chosen as a model system. The 
virus replication efficacy in these two cell lines was radi-
cally different. The number of GFP-producing cells cor-
responding to viral protein production as well as the 
reproduction of infectious virus in KB-3-1 and KB-8-5 
cells was much higher than the same infection param-
eters in RLS and RLS-40 cells. However, the replica-
tion efficacy was the same in KB-3-1 and KB-8-5 cells, 
as was the efficacy of viral protein expression and cells 
killed by virus. On the basis of these results, it is likely 
that the virotherapy with LIVP-GFP mice bearing KB-8-5 
tumours with the MDR phenotype as well as the parental 
tumours KB-3-1 could be successful and it remains to be 
tested in future experiments.
LIVP-GFP production in RLS cells increased very 
slightly over the observation period and reached its 
highest level at 48  hpi. The viral titre in RLS-40 lym-
phosarcoma cells remained unchanged throughout the 
entire period of observation. It is interesting to note 
that a tenfold MOI increase did not result in increased 
virus reproduction but only in a higher number of GFP-
producing cells and MFI of infected cells. Virus replica-
tion analysis in B-16 murine melanoma cells showed 
relatively high susceptibility of these cells to the virus, 
where a MOI increase correlated with an increase in the 
number of newly synthesized viral particles peaking at 
48 hpi (Fig. 3). Reduced efficiency of viral replication in 
B-16 cells as compared to KB-3-1 and KB-8-5 cells may 
be associated with generally less effective viral replication 
in murine cells than in human cells [38, 39]. In turn, the 
reduced susceptibility of RLS and RLS-40 shown in this 
study is consistent with the findings of other research-
ers showing the low viral replication efficacy in pri-
mary human leukocyte subsets including monocytes, 
B cells, NK cells (both in resting and activated states), 
Fig. 5 The effects of LIVP-GFP virus on tumour growth, metastasis development and lifespan of tumour-bearing mice. a Scheme of the experi-
ments. b, d Inhibition of melanoma B-16 (b) and lymphosarcoma RLS-40 (d) tumour growth after treatment with LIVP-GFP. Mice with tumours 
implanted subcutaneously for melanoma B-16 or intramuscularly for RLS-40 received two injections of either LIVP-GFP or PBS intratumourally. 
Tumour volume was monitored every other day, and the mean ± SD are shown; asterisk denotes statistically significant difference with P < 0.05.  
c Lifespan of mice with melanoma-B-16 treated with LIVP-GFP (open squares) or PBS (grey rhombus). Mouse survival was monitored for 60 days after 
tumour implantation. e The effect of LIVP-GFP (white bar) on metastasis development in mice with RLS-40 tumour (black bar mice received PBS)
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neutrophils, and resting T cells [40–42]. Taken together, 
the results of in  vitro analysis indicate that different 
tumour cell lines with MDR phenotypes demonstrated 
different susceptibilities to LIVP-GFP, which depend on 
the ability of virus to replicate in these cells.
Oncolytic vectors are supposed to destroy tumour 
cells in two phases: after viral replication in cells and 
after induction of an immune response against viral anti-
gens expressed in tumour cells (immunologically medi-
ated destruction). Recently, it was shown that vaccinia 
virus infection induces necrotic death in ovarian cancer 
cells [43]. Destruction of vaccinia virus infected tumor 
cells leads to the release of tumour associated antigens 
and danger signals into extra-cellular surrounding and 
tumour microenvironment [44]. Such danger signals 
could be sensed by cells of innate immune system, so it 
could be suggested that activation of innate immune 
system might take part in tumor regression in coop-
eration with the viral oncolytic process [45]. Moreover, 
most recently, Zonov et al. demonstrated that direct cell 
destruction have been implicated in vaccinia infection of 
human carcinoma A431 cells, but in Ehrlich carcinoma 
cells which poorly supported vaccinia virus replication 
the virus induced suppression of mitoses [46]. However, 
nowadays the mechanisms mediating death of vaccinia 
virus infected cells are not clear entirely. In particular, for 
some cancer cells it was shown that apoptosis is a main 
pathway of vaccinia virus infected cell death [47].
Since viral replication has not been observed in RLS-
40 lymphosarcoma cells (in vitro and in  vivo), the inhi-
bition of tumour growth in immunocompetent mouse 
model CBA—RLS-40 lymphosarcoma after treatment 
with LIVP-GFP would mainly depend on the reaction 
of the host immune system to the virus injection. Given 
the high immunostimulatory activity of the virus, it was 
interesting to assess the effectiveness of virotherapy in 
such a system. A similar study was conducted by Prest-
wich and colleagues [48] with oncolytic reovirus and reo-
virus-nonpermissive tumours, which allowed the authors 
to focus on the role of the virus in the activation of the 
immune system. In addition, we compared the antitu-
mour efficacy of LIVP-GFP in RLS-40 lymphosarcoma 
cells with melanoma B-16 in immunocompetent mice, 
taking into consideration the differential ability of LIVP-
GFP to replicate and kill cells in this tumour cell line. We 
had previously determined that intratumoural admin-
istration of the LIVP-GFP virus resulted in a significant 
inhibition of tumour growth in mice bearing melanoma 
B-16 [28]. Inhibition of the growth of such a quick-grow-
ing tumours as melanoma B16 after a single administra-
tion of the LIVP–GFP virus indicates its high antitumour 
potential. Since complete tumour regression after a 
Fig. 6 The effect of LIVP-GFP on metastasis development in liver of mice with RLS-40. a Liver sections of intact mice or mice with RLS-40 that 
received intratumoural injections of PBS or LIVP-GFP. The number of metastases found in each group of mice is shown below the corresponding 
section. Arrows show the most visible metastasis. Haematoxylin and eosin staining. b Histopathological analysis of the liver tissue of intact (left) or 
RLS-40-bearing mice receiving PBS (centre) or LIVP-GFP (right)
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single administration of virus was not obtained, we opti-
mized the viral application procedure. The virus was now 
injected twice: immediately after tumour implantation 
and 4 days after.
Usually, intravenous or intratumoural routs of vac-
cinia virus administration are used. Oncolytic vaccinia 
virus injected intravenously is able to infect and replicate 
within cancer cells but intravenous delivery of the virus 
would result in a drastic loss of the virus in the blood 
stream mainly due to the rapid clearance by immune sys-
tem [49]. Direct intratumoural vaccinia application may 
be useful in treating locally aggressive tumors and now 
randomized dose-finding trial of Pexa-Vec in patients 
with advanced HCC showed promising results. In this 
trial Pexa-Vec was delivered by intratumoural injection 
[50]. Intratumoural delivery also allows using of lower 
virus doses and probably postpones antiviral immune 
response. Besides, intratumoural virus administration 
could provide higher multiplicity of infection of tumour 
cells. For these reason we used in our study direct intra-
tumoural administration of LIVP-GFP.
Consistent with our previous results, LIVP-GFP signifi-
cantly inhibited the growth of melanoma B-16 in mice. 
The optimization of the treatment strategy has led to an 
increased survival benefit: 33 % of animals in the group 
bearing melanoma B-16 treated with the virus showed a 
complete response and survived, while control animals 
did not survive. We also demonstrated that the adminis-
tration of LIVP-GFP twice in the early stages of tumour 
development is able to inhibit the growth of malignant 
RLS-40 cells with the MDR phenotype, as well as tumour 
metastasis. We hypothesize that two mechanisms under-
lie the effects of virotherapy of these tumours. A direct 
oncolysis is induced by the virus in the case of melanoma 
B-16 because the virus effectively replicates and destroys 
these tumour cells, and virus-mediated activation of the 
host immune system is followed by immunologically 
mediated destruction of lymphosarcoma RLS-40. In 
order to exam whether the mechanism of inhibition of 
RLS-40 lymphosarcoma displaying the MDR phenotype 
was mediated by activation of the immune system, we 
estimated the generation CD8 T-cells after treatment of 
mice with LIVP-GFP.
It is known that the vaccinia virus is capable of gen-
erating a highly specific T-cell immune response [51]. 
According to recent studies [52], it is also known that 
activation of a T-cell immune response significantly 
contributes to the development of antitumour immu-
nity. Therefore, it is important to evaluate the efficiency 
of T-cell immune response induction by the LIVP-GFP 
Fig. 7 Effect of LIVP-GFP treatment on the immune responses of 
tumour-bearing mice. a Summary data showing a significant increase 
of the number of IFN-γ-ransecreting splenocytes in LIVP-GFP-treated 
mice (n = 6) with RLS-40 or with melanoma B-16 tumours. Compari-
son of immune-related proteins GMC-SF (b) and IL-6 (c) in the blood 
serum of RLS-40 bearing mice during the treatment with LIVP-GFP 
(the experimental scheme was shown in Fig. 5a): red circles and blue 
squares for RLS-40 bearing mice treated with LIVP-GFP and PBS, 
respectively; black triangles—healthy mice receiving PBS. The levels of 
cytokines in the blood serum were measured by ELISA. For each day, 
the value of MEAN ± SEM is shown
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virotherapy. We observed a significant (tenfold) increase 
in the number of virus-specific IFN-γ -producing cells 
after virus injection. Although tumour-specific IFN-γ-
secreting cells were not observed, it has been shown that 
adaptive cytotoxic T-cell responses can promote power-
ful activation of innate immune effector cells [53] and 
generate a highly immunogenic environment [39]. We 
assume that the stimulation of T-cell immunity resulted 
in a decrease in the number of metastases in animals 
with implanted RLS-40 cells after two injections of the 
virus. A reduction in the number of metastases after a 
CD8+ T lymphocyte increase has also been shown in 
Wang et  al. [39]. These authors showed that removal of 
CD4 lymphocytes, neutrophils and NK cells popula-
tions had no effect on the anti-metastatic activity of the 
virus. It worth noting that results obtained with a math-
ematical model of virotherapy indicated that while viral 
oncolysis is fundamental in reducing the tumour burden, 
increased stimulation of cytotoxic T cells leads to a short-
term reduction in tumour size, but a faster relapse [54]. 
It was hypothesized that viral destruction of melanoma 
B-16 cells resulted in more effective tumour elimination 
compared to the outcome of viral therapy in RLS-40 lym-
phosarcoma-bearing mice.
In addition to virus-specific T-cell activation, we 
assessed the humoral immune response in RLS-40 
lymphosarcoma-bearing mice after treatment with 
either LIVP-GFP or PBS. The activation of the humoral 
immune system during virotherapy has been tested in 
various studies [55–57], but in general the authors ana-
lysed the levels and the spectrum of cytokines present 
in tumour tissue or by culturing infected tumour cells. 
The experiments revealed no significant fluctuations 
in the level of GM-CSF, IFN-γ, TNF-α during the entire 
period of observation; however, we found a dramatic 
increase in the concentration of IL-6 in mice in the con-
trol group (treatment with PBS), which coincides with 
a sharp increase in the size of the tumours. In contrast, 
IL-6 levels were the same in the experimental group as 
those of intact animals. IL-6 is a pleiotropic cytokine that 
induces an active phase of the immune response, stimu-
lates activation of B and T lymphocytes, and regulates 
growth, differentiation and death of certain cell popula-
tions [58]. Binding of IL-6 to its receptor complex leads 
to JAK activation followed by subsequent phosphoryla-
tion and dimerization of NF-kB and STAT-3. IL-6 is one 
of the key cytokines involved in the proliferation and dif-
ferentiation of tumour cells [59]. Moreover, it was shown 
that IL-6 promotes tumor growth by VEGF-dependent 
angiogenesis in particular via a STAT3 pathway [59–61]. 
Taking in account that IL-6 takes part in regulation of 
VEGF expression we can speculate that decreasing of 
level IL-6 after therapy of tumor with LIVP-GFP might 
lead to decreasing of VEFR’s level thus affecting tumour 
vasculature. Significant reducing of VEGF levels in the 
tumor of mice treated intravenously with vaccinia virus 
was shown recently [62].
IL-6 stimulates the development of many tumours, 
including glioma [63], multiple myeloma [64] and colo-
rectal carcinoma [65]. IL-6 overexpression and its recep-
tors may be associated with increased proliferation of 
breast cancer cells [66]. Given the role of IL-6 in the 
activation of androgen receptors, neuroendocrine dif-
ferentiation and angiogenesis in prostate cancer develop-
ment, attempts have been made to inhibit the cytokine 
signalling pathways using monoclonal antibodies [67]. 
Inhibition of tumour growth in IL-6 knockout mice also 
indicates the role of IL-6 in stimulation of tumour devel-
opment [68]. Whether the inhibition of IL-6 is a key 
factor in inhibition of RLS-40 lymphosarcoma growth 
remains to be seen in future experiments.
An increase in the immunostimulatory properties of 
VACV is implemented in a number of new approaches 
to virotherapy use in cancer treatment. In addition to 
cytokines and immunostimulatory molecules embed-
ded in the viral genome, a method of using so-called T 
cell-engagers that can bind T cells to tumour cells and 
additionally induce immune-mediated tumour cell 
destruction was proposed [69]. In other studies, cytokine-
induced killer (CIK) cells were used as a vector for VACV 
systemic delivery [38, 70]. A few other approaches that 
can also have a direct impact on the immune responses 
induced by the viral vectors have been devised [71]. Fur-
thermore, to enhance the antitumour effect of vaccinia 
virus Teigler with colleagues [72] suggest considering the 
variability of the immune response induced by the vector. 
Given the diversity and the effectiveness of pro-inflam-
matory cytokine and chemokine responses, research-
ers have the flexibility to choose a vector for activation 
of cytokines responsible for tumour growth inhibition, 
which in combination with other methods of virotherapy 
may be an effective way to eliminate cancer cells.
Understanding the mechanisms of resistance and sus-
ceptibility of various tumours to the action of oncolytic 
viruses, the choice of a vector for cautious activation of 
an immune response and the use of combination therapy 
to enhance the effectiveness of the virotherapy is neces-
sary to develop such an approach to anticancer therapy 
and remains a subject of further research.
Conclusions
Chemotherapy is likely to be the main treatment 
approach for cancer for a long time to come. An effec-
tive co-treatment in order to achieve solid regression of 
the tumour would be adjuvants with various mechanisms 
of action, and oncolytic viruses have many advantages 
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among other candidates. The data we obtained show that 
the anti-tumour activity of LIVP-GFP detected in case of 
melanoma B-16 was a result of direct oncolysis of tumour 
cells because the virus effectively replicates and destroys 
these cells. We demonstrated that virus-mediated activa-
tion of the host immune system is followed by immuno-
logically mediated destruction of lymphosarcoma RLS-40. 
Thus, the recombinant vaccinia virus LIVP-GFP is able to 
inhibit the growth of malignant cells with the MDR phe-
notype and tumour metastasis when administered in the 
early stages of tumour development either by direct onco-
lysis of tumour cells or by activation of the host immune 
system. In addition, the data on the immunostimulatory 
activity of vaccinia virus can be applied to develop more 
efficient schemes for virotherapy in cancer diseases.
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